Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges.

Tytuł:: Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges.
Autorzy:: Ten Haaf K; Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.
van der Aalst CM; Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.
de Koning HJ; Department of Public Health, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.
Kaaks R; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Translational Lung Research Center (TLRC) Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.
Tammemägi MC; Department of Health Sciences, Brock University, St. Catharines, Ontario, Canada.
Źródło:: International journal of cancer [Int J Cancer] 2021 Jul 15; Vol. 149 (2), pp. 250-263. Date of Electronic Publication: 2021 May 03.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Publication: 1995- : New York, NY : Wiley-Liss
Original Publication: 1966-1984 : Genève : International Union Against Cancer
MeSH Terms:: Lung Neoplasms/*diagnosis
Precision Medicine/*methods
Smoking/*epidemiology
Early Detection of Cancer ; Healthcare Disparities ; Humans ; Lung Neoplasms/chemically induced ; Randomized Controlled Trials as Topic ; Risk Assessment ; Smoking/adverse effects
References:: JAMA Oncol. 2019 Sep 1;5(9):1318-1324. (PMID: 31246249)
BMC Cancer. 2016 Apr 20;16:281. (PMID: 27098676)
EBioMedicine. 2018 May;31:36-46. (PMID: 29678673)
BMJ. 2017 Feb 8;356:j347. (PMID: 28179230)
Nicotine Tob Res. 2016 Jul;18(7):1665-9. (PMID: 26834052)
Br J Cancer. 2008 Jan 29;98(2):270-6. (PMID: 18087271)
N Engl J Med. 2011 Aug 4;365(5):395-409. (PMID: 21714641)
Lancet Respir Med. 2016 Sep;4(9):749-761. (PMID: 27599248)
Eur Respir J. 2013 Dec;42(6):1659-67. (PMID: 23845716)
BMJ Open. 2020 Sep 10;10(9):e037075. (PMID: 32912947)
Epidemiol Rev. 2011;33:135-47. (PMID: 21586673)
Cancer Prev Res (Phila). 2012 Jun;5(6):834-46. (PMID: 22496387)
AJR Am J Roentgenol. 2018 Mar;210(3):514-517. (PMID: 29261350)
Ann Intern Med. 2014 Mar 4;160(5):330-8. (PMID: 24378917)
Biostatistics. 2016 Jan;17(1):149-64. (PMID: 26319700)
J Thorac Cardiovasc Surg. 2012 Jul;144(1):33-8. (PMID: 22710039)
Transl Lung Cancer Res. 2021 Feb;10(2):1141-1153. (PMID: 33718052)
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):154-61. (PMID: 25312998)
Transl Lung Cancer Res. 2021 Feb;10(2):1099-1109. (PMID: 33718048)
Lancet Oncol. 2019 Aug;20(8):1098-1108. (PMID: 31255490)
J Natl Cancer Inst. 2010 Dec 1;102(23):1771-9. (PMID: 21119104)
JAMA Intern Med. 2014 Feb 1;174(2):281-5. (PMID: 24322781)
J Natl Cancer Inst. 2020 Nov 1;112(11):1136-1142. (PMID: 32040195)
Lancet Oncol. 2017 Nov;18(11):1523-1531. (PMID: 29055736)
N Engl J Med. 1980 May 15;302(20):1109-17. (PMID: 7366635)
PLoS Med. 2014 Dec 02;11(12):e1001764. (PMID: 25460915)
Transl Lung Cancer Res. 2021 Mar;10(3):1305-1317. (PMID: 33889511)
Prev Med. 2001 Oct;33(4):325-32. (PMID: 11570837)
PLoS One. 2015 Mar 30;10(3):e0121323. (PMID: 25822850)
Cancer. 2013 Nov 15;119(22):3976-83. (PMID: 24037918)
J Natl Cancer Inst. 2003 Mar 19;95(6):470-8. (PMID: 12644540)
Ann Am Thorac Soc. 2017 Dec;14(12):1827-1835. (PMID: 28683215)
Ann Thorac Surg. 2021 Jun;111(6):1805-1811. (PMID: 33039364)
J Natl Cancer Inst. 2020 May 1;112(5):466-479. (PMID: 31566216)
Lancet. 2019 Apr 20;393(10181):1577-1579. (PMID: 31007185)
Ann Intern Med. 2015 Apr 7;162(7):485-91. (PMID: 25664444)
Br J Radiol. 2018 Apr;91(1084):20170284. (PMID: 29334237)
J Med Screen. 2018 Jun;25(2):110-112. (PMID: 28929865)
Thorax. 2018 Mar 30;:. (PMID: 29602813)
Med Decis Making. 2015 Feb;35(2):183-95. (PMID: 24739535)
Am J Respir Crit Care Med. 2018 Jul 15;198(2):e3-e13. (PMID: 30004250)
PLoS Med. 2017 Apr 4;14(4):e1002277. (PMID: 28376113)
Lancet Oncol. 2016 May;17(5):590-9. (PMID: 27009070)
JAMA. 2016 Jun 7;315(21):2300-11. (PMID: 27179989)
Cancer Causes Control. 2008 Apr;19(3):317-28. (PMID: 18058248)
Am J Prev Med. 2019 Jan;56(1):66-73. (PMID: 30467092)
J Natl Cancer Inst. 2007 May 2;99(9):715-26. (PMID: 17470739)
JAMA Intern Med. 2017 Mar 1;177(3):439-441. (PMID: 28135349)
N Engl J Med. 2013 Feb 21;368(8):728-36. (PMID: 23425165)
Thorax. 2017 Sep;72(9):819-824. (PMID: 28360223)
PLoS Med. 2017 Feb 7;14(2):e1002225. (PMID: 28170394)
J Med Screen. 2008;15(3):153-8. (PMID: 18927099)
Cancer Causes Control. 2019 Mar;30(3):235-240. (PMID: 30377905)
Nat Med. 2019 Jun;25(6):954-961. (PMID: 31110349)
Br J Cancer. 2010 Nov 9;103(10):1496-501. (PMID: 20959827)
Med Decis Making. 2006 Nov-Dec;26(6):565-74. (PMID: 17099194)
J Epidemiol Community Health (1978). 1978 Dec;32(4):303-13. (PMID: 744822)
Ann Intern Med. 2012 Aug 21;157(4):242-50. (PMID: 22910935)
Am J Respir Crit Care Med. 2020 Apr 15;201(8):965-975. (PMID: 31825647)
Int J Cancer. 2021 Jul 15;149(2):250-263. (PMID: 33783822)
Ann Intern Med. 2019 Dec 3;171(11):796-804. (PMID: 31683314)
Eur Respir J. 2020 Feb 12;55(2):. (PMID: 32051182)
AJR Am J Roentgenol. 2006 Aug;187(2):421-9. (PMID: 16861547)
J R Stat Soc Ser A Stat Soc. 2009 Oct 1;172(4):729-748. (PMID: 20069131)
PLoS Med. 2012;9(5):1-12. (PMID: 22629234)
Diagn Progn Res. 2017;1:12. (PMID: 29350215)
Int J Cancer. 2020 Mar 15;146(6):1503-1513. (PMID: 31162856)
JAMA Oncol. 2018 Oct 1;4(10):e182078. (PMID: 30003238)
Health Technol Assess. 2016 May;20(40):1-146. (PMID: 27224642)
JAMA Intern Med. 2019 May 1;179(5):716-718. (PMID: 30640388)
Lancet Oncol. 2017 Dec;18(12):e754-e766. (PMID: 29208441)
Eur Heart J Cardiovasc Imaging. 2020 Oct 20;21(11):1216-1224. (PMID: 32584979)
J Clin Epidemiol. 2016 Jun;74:167-76. (PMID: 26772608)
Am J Prev Med. 2014 Sep;47(3):251-9. (PMID: 24923862)
JAMA Netw Open. 2019 Mar 1;2(3):e190204. (PMID: 30821827)
J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716)
Radiology. 2011 Jan;258(1):243-53. (PMID: 21045183)
BMJ. 2010 Oct 26;341:c5370. (PMID: 20978060)
Ann Intern Med. 2018 Jul 3;169(1):10-19. (PMID: 29800127)
N Engl J Med. 2020 Feb 6;382(6):503-513. (PMID: 31995683)
Ann Am Thorac Soc. 2020 Apr;17(4):503-512. (PMID: 32011914)
Transl Lung Cancer Res. 2018 Jun;7(3):327-335. (PMID: 30050770)
J Thorac Oncol. 2020 Jul;15(7):1160-1169. (PMID: 32160967)
Best Pract Res Clin Gastroenterol. 2010 Aug;24(4):465-78. (PMID: 20833350)
Am J Respir Crit Care Med. 2016 Mar 1;193(5):542-51. (PMID: 26485620)
Eur J Cancer. 2019 Sep;118:142-148. (PMID: 31336289)
Lung Cancer. 2014 Apr;84(1):13-22. (PMID: 24524818)
Eur Respir J. 2021 Jan 14;57(1):. (PMID: 32732334)
J Thorac Oncol. 2017 Aug;12(8):1210-1222. (PMID: 28499861)
BMC Med Res Methodol. 2014 Mar 19;14:40. (PMID: 24645774)
Thorax. 2020 Aug;75(8):661-668. (PMID: 32631933)
Ann Intern Med. 2013 Sep 17;159(6):411-420. (PMID: 23897166)
J Natl Cancer Inst. 2019 Sep 1;111(9):996-999. (PMID: 30976808)
Ann Intern Med. 2014 Mar 4;160(5):311-20. (PMID: 24379002)
Transl Lung Cancer Res. 2021 Jan;10(1):233-242. (PMID: 33569307)
Int J Cancer. 2017 Jul 15;141(2):242-253. (PMID: 28249359)
Thorax. 2017 Oct;72(10):912-918. (PMID: 28710339)
Int J Cancer. 2003 Mar 1;103(6):792-802. (PMID: 12516101)
J Thorac Oncol. 2015 May;10(5):747-753. (PMID: 25664626)
Cancer Res. 2021 Mar 15;81(6):1607-1615. (PMID: 33472890)
J Natl Cancer Inst. 2014 May 28;106(6):dju084. (PMID: 24872540)
PLoS One. 2018 Jan 10;13(1):e0190171. (PMID: 29320536)
PLoS One. 2015 Nov 30;10(11):e0143789. (PMID: 26618478)
J Thorac Oncol. 2015 Sep;10(9):1285-1291. (PMID: 26287320)
Sci Rep. 2017 Apr 19;7:46479. (PMID: 28422152)
Br J Cancer. 2010 Jul 27;103(3):423-9. (PMID: 20588271)
Jpn J Radiol. 2015 May;33(5):266-72. (PMID: 25787900)
Med Decis Making. 2010 Jan-Feb;30(1):35-44. (PMID: 19692709)
Cancer Prev Res (Phila). 2015 Sep;8(9):777-85. (PMID: 26076698)
Am J Respir Crit Care Med. 2015 May 15;191(10):1166-75. (PMID: 25760561)
JAMA. 2021 Mar 9;325(10):962-970. (PMID: 33687470)
BMC Med. 2019 Dec 16;17(1):230. (PMID: 31842878)
Radiology. 2004 May;231(2):440-5. (PMID: 15128988)
Am J Respir Crit Care Med. 2020 Oct 1;202(7):e95-e112. (PMID: 33000953)
Ann Am Thorac Soc. 2017 Oct;14(10):1571-1580. (PMID: 28541748)
Thorax. 2021 Feb;76(2):161-168. (PMID: 33082166)
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
J Thorac Oncol. 2019 Sep;14(9):1528-1537. (PMID: 31077790)
Transl Lung Cancer Res. 2018 Aug;7(4):450-463. (PMID: 30225210)
JAMA. 2021 Mar 9;325(10):988-997. (PMID: 33687469)
Cancer Prev Res (Phila). 2014 Mar;7(3):362-71. (PMID: 24441672)
Int J Epidemiol. 1990;19 Suppl 1:S14-23. (PMID: 2258272)
JAMA. 2021 Mar 9;325(10):971-987. (PMID: 33687468)
Thorax. 2017 Sep;72(9):825-831. (PMID: 28377492)
Lung Cancer. 2020 Oct;148:12-19. (PMID: 32771715)
Lung Cancer. 2019 Aug;134:66-71. (PMID: 31319997)
BMC Cancer. 2010 Jun 14;10:285. (PMID: 20546590)
Lancet Oncol. 2014 Nov;15(12):1332-41. (PMID: 25282285)
J Thorac Imaging. 2019 May;34(3):160-169. (PMID: 30550403)
J Thorac Oncol. 2020 Nov;15(11):1738-1747. (PMID: 32822843)
JAMA. 2012 Oct 10;308(14):1433-4. (PMID: 23047354)
Stat Methods Med Res. 2018 Jan;27(1):185-197. (PMID: 27460537)
JAMA Oncol. 2020 May 1;6(5):714-723. (PMID: 32134442)
N Engl J Med. 2006 Jan 26;354(4):333-42. (PMID: 16436765)
Clin Lung Cancer. 2017 Sep;18(5):e327-e331. (PMID: 28237242)
Thorax. 2020 Oct;75(10):831-832. (PMID: 32792406)
Public Health Rev. 2018 Aug 15;39:23. (PMID: 30128168)
Ann Intern Med. 2018 Feb 6;168(3):161-169. (PMID: 29297005)
Lung Cancer. 2018 Jul;121:61-69. (PMID: 29858029)
J Am Coll Radiol. 2015 Jul;12(7):664-9. (PMID: 25972250)
Am J Respir Crit Care Med. 2018 Jan 15;197(2):172-182. (PMID: 28977754)
Thorax. 2019 Apr;74(4):405-409. (PMID: 29440588)
J Natl Compr Canc Netw. 2018 Apr;16(4):412-441. (PMID: 29632061)
J Clin Epidemiol. 2005 Apr;58(4):383-90. (PMID: 15862724)
BMJ Open. 2015 Jul 14;5(7):e008254. (PMID: 26173719)
J Gen Intern Med. 2019 Aug;34(8):1538-1545. (PMID: 31147981)
Eur Respir J. 2011 Jun;37(6):1466-73. (PMID: 21148233)
BMJ Open. 2020 Sep 10;10(9):e037086. (PMID: 32912948)
Ann Intern Med. 2019 Nov 5;171(9):623-632. (PMID: 31634914)
BMC Med. 2019 Oct 25;17(1):192. (PMID: 31651317)
J Natl Cancer Inst. 2021 Jan 23;:. (PMID: 33484569)
N Engl J Med. 2018 May 24;378(21):1999-2009. (PMID: 29791813)
Int J Cancer. 2007 Feb 15;120(4):868-74. (PMID: 17131307)
J Thorac Oncol. 2019 Mar;14(3):343-357. (PMID: 30529598)
Am J Prev Med. 2015 Dec;49(6):e125-9. (PMID: 26456873)
Int J Cancer. 2017 Jun 1;140(11):2436-2443. (PMID: 28073150)
Nat Rev Cancer. 2007 Oct;7(10):778-90. (PMID: 17882278)
N Engl J Med. 2013 Jul 18;369(3):245-254. (PMID: 23863051)
Am J Epidemiol. 2010 Oct 15;172(8):971-80. (PMID: 20807737)
Eur J Epidemiol. 2020 Oct;35(10):899-912. (PMID: 32594286)
BMJ. 2020 Mar 25;368:m689. (PMID: 32213531)
Contributed Indexing:: Keywords: lung cancer screening; personalised screening; risk-based screening
Entry Date(s):: Date Created: 20210330 Date Completed: 20210907 Latest Revision: 20210907
Update Code:: 20240105
PubMed Central ID:: PMC8251929
DOI:: 10.1002/ijc.33578
PMID:: 33783822
: Czasopismo naukowe

Full Text Finder

Randomised clinical trials have shown the efficacy of computed tomography lung cancer screening, initiating discussions on whether and how to implement population-based screening programs. Due to smoking behaviour being the primary risk-factor for lung cancer and part of the criteria for determining screening eligibility, lung cancer screening is inherently risk-based. In fact, the selection of high-risk individuals has been shown to be essential in implementing lung cancer screening in a cost-effective manner. Furthermore, studies have shown that further risk-stratification may improve screening efficiency, allow personalisation of the screening interval and reduce health disparities. However, implementing risk-based lung cancer screening programs also requires overcoming a number of challenges. There are indications that risk-based approaches can negatively influence the trade-off between individual benefits and harms if not applied thoughtfully. Large-scale implementation of targeted, risk-based screening programs has been limited thus far. Consequently, questions remain on how to efficiently identify and invite high-risk individuals from the general population. Finally, while risk-based approaches may increase screening program efficiency, efficiency should be balanced with the overall impact of the screening program. In this review, we will address the opportunities and challenges in applying risk-stratification in different aspects of lung cancer screening programs, as well as the balance between screening program efficiency and impact.
(© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control.)

Erratum in: Int J Cancer. 2021 Oct 15;149(8):E13. (PMID: 34293198)

Informacja